|
 
 |
| REVIEW ARTICLE |
|
| Year : 2011 | Volume
: 3
| Issue : 1 | Page : 13-19 |
|
Natural products and body weight control
Jay Lee1, Yanmei Li1, Chunhua Li1, Duo Li2
1 Department of Research & Development, Beijing Gingko Group, Beijing, 100081, China
2 Department of Food Science & Nutrition, Zhejiang University, Hangzhou, 310058, China
| Date of Web Publication | 9-Nov-2011 |
Correspondence Address:
Duo Li
Department of Food Science and Nutrition, Zhejiang University, 388 Yu-Hang-Tang Road, Hangzhou, Zhejiang, 310058
China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4297/najms.2011.313
The purpose of the review was to summarise the effect of some commonly available natural products used for body weight management. We collected data from PubMed and scientific journals. There are numerous publications on this topic, however we have summarized the most commonly available and potent natural products from recent 53 publications. The natural products analyzed in this paper include catechins, capsaicin, conjugated linoleic acid, fucoxanthin, soy isoflavone, glabridin, astaxanthin and cyaniding-3-glucoside. These natural products are effective and safe for body weight management. Further studies need to be conducted to investigate the mechanism of action, metabolism, long term safety and side effects of these natural products, as well as interactions between these natural products with dietary components. Keywords: Natural products, obesity, catechins, capsaicin, conjugated linoleic acid, fucoxanthin, soy isoflavone, glabridin, astaxanthin, cyaniding-3-glucoside.
How to cite this article:
Lee J, Li Y, Li C, Li D. Natural products and body weight control. North Am J Med Sci 2011;3:13-9 |
| Introduction | |  |
Obesity is a worldwide epidemic with prevalence increasing year on year. WHO estimated that by 2015, there will be more than 1.5 billion people overweight, incurring health costs beyond $117 billion per year in the US alone. The opportunities for scientifically substantiated food products used for body weight management are impressive. Diet and lifestyle changes remain the cornerstone of therapy for obesity, but the resultant weight loss is often small and long-term success is extremely uncommon and disappointing. Drug therapy has been considered for individuals with a body mass index (BMI) greater than 30 kg/m 2 , or 25 to 30 kg/m 2 if person suffers from other co-morbidities. Antiobesity agents can be used for some patients to help achieve and maintain meaningful weight loss, but these pharmaceuticals are of limited effectiveness in the face this worldwide problem. At present, only two drugs, orlistat and sibutramine, are approved for long-term use in the treatment of obesity, and each of these typically promotes 5% to 10% loss of total body weight [1] . Although very effective in promoting clinically meaningful weight loss, reduction in waist circumference and improvements in several metabolic risk factors, rimonabant, a cannabinoid-1 receptor antagonist, was withdrawn from the market due to concerns about its safety, including risk of suicide and seizures [2],[3] .
Natural ingredients are effective and practical remedies for treatment of obesity, and relatively safe. The most popular supplements are catechins, capsaicin, soy isoflavone, fucoxanthin, glabridin, conjugated linoleic acid, astaxanthin, cyaniding-3-glucoside etc.
| Catechins | | |
Catechins are a group of polyphenolic compounds found in tea [4] . In general, green tea contains about 30% w/w catechins in the dry tea leaves. The major catechins, which are found in abundant proportion, are (-)-epigallocatechin gallate (EGCG) [Figure 1]A, (-)-epigallocatechin [Figure 1]B, (-)-epicatechin [Figure 1]C and (-)-epicatechin gallate [Figure 1]D, with EGCG amounting to over 60% of the total catechins [5] . Other compounds obtainable in green tea are the flavonols (quercetin, kaempferol and rutin), caffeine, phenolic acids, theanine, and flavour compounds. Black tea contains less tea catechins (3-10% w/w), while theaflavins and thearubigins account for about 2-6% w/w and 10-20% w/w of the dry weight of the tea leaves, respectively [4] . | Figure 1A: (—)-epigallocatechin gallate
Figure 1B: (—)-epigallocatechin
Figure1C: (—)-epicatechin
Figure 1D: (—)-epicatechin gallate
Click here to view |
It is known that green tea possesses various biological functions. Ingestion of high dose catechins results in loss of body and adipose tissue weights, and regulation of lipid metabolism [6] .
Green tea and its extracts have been shown to increase energy expenditure and fat oxidation in the short term in both animals and humans. In a randomized, controlled trial, 60 Thai obese subjects (BMI > 25kg/m 2 ) were randomized into green tea and control groups. Body weight reduction, resting energy expenditure and respiratory quotient were significantly different between the two groups (p<0.05) at 8 weeks, with no significant differences on satiety score, food intake and physical activity. Urine vanillylmandelic acid was significantly higher in green tea group than in control at 12 weeks (p<0.05) [7] . Green tea extract along with a low-energy diet resulted in modest weight loss, improved HDL-cholesterol and blood pressure, but had no effect on other parameters [8] . Eva et al. suggested that weight maintenance after 7.5% body-weight loss was not affected by green tea, and that habitual caffeine consumption affected weight maintenance in the green tea treatment [9] . EGCG apparently promoted fat oxidation, but its fat-reducing effect could be explained by its effect in reducing diet digestibility [10] .
Green tea extract exhibits marked inhibition of digestive lipases in vitro, which is likely to reduce fat digestion in humans [11] . Catechins prevent obesity through the suppression of adipocyte differentiation [12] . EGCG can act directly to inhibit differentiation of preadipocytes and to induce apoptosis of mature adipocytes [13] as indicated by formation of DNA fragments which was induced by EGCG in dose-dependent manners [14] .
| Capsaicin | | |
Capsaicin is the active ingredient of hot pepper, it not only adds spice to foods, but can cause the body to heat up, promoting calorie expenditure. It is a potent afferent nerve stimulant.[Figure 2]
Epidemiological data revealed that the consumption of foods containing capsaicin was associated with a lower prevalence of obesity. In experimental studies, when oral capsaicin was provided to rodents as 0.014% of the diet; a dose equivalent to that ingested by rural Thai people, there was a significant 24% and 29% reduction in the weight of visceral (peri-renal) fat, but no effect on total caloric intake [15] . Systemic treatment with capsaicin or its analogue is an accepted experimental method to induce functional ablation of the capsaicin-sensitive afferent nerves at different body sites [16] . Such functional impairment retarded body weight gain and reduced total body fat in rats. The capsaicin (vanilloid) receptor agonist (resiniferatoxin) reduced body fat and body weight and improved glucose tolerance in obese rats [17],[18] . Although the effect on subcutaneous fat was not assessed, these two studies suggest the possibility that oral capsaicin treatment might regulate adipose tissue distribution. Since capsaicin absorbed from the gut lumen is almost completely metabolized before reaching the general circulation, a direct effect of oral capsaicin on adipose tissue at remote sites is unlikely. In support of this is also the fact that repeated administration of oral capsaicin functionally desensitized the intestinal mucosal but not the corneal afferent nerves. Taking this information into account, if oral capsaicin could regulate adipose tissue distribution, the process might involve the intestinal mucosal afferent nerves [19],[20] . Capsaicin-sensitive intestinal mucosal afferent mechanism plays a role in regulating body fat distribution.
In an intervention study, 34 subjects were randomized to take either placebo or supplements containing the non-burning pepper analog dihydrocapsiate (DCT) for 28 days. Two dosage levels of DCT were tested. At the beginning and end of the study, body weight and body fat were assessed, and energy expenditure (heat production) in each subject after he or she consumed one serving of the test meal was determined. Results showed that energy expenditure was significantly increased in the group consuming the higher amount of DCT. In fact, it was almost double that of the placebo group. This suggests eating this pepper-derived substance that doesn't burn can have the same potential benefit as hot peppers at least in part by increasing food-induced heat production. They were also able to show that DCT significantly increased fat oxidation, pushing the body to use more fat as fuel [21] .
Cell culture studies showed that capsaicin has a direct effect on adipocytes [22] . Oral capsaicin significantly increases transient receptor potential vanilloid type-1 (TRPV1) channel expression as well as TRPV1 messenger ribonucleic acid (mRNA) in visceral adipose tissue [23] .
| Fucoxanthin | | |
Fucoxanthin, a member of the carotinoid family, is extracted from edible seaweed and undaria pinnatifida, etc.[Figure 3]
Animal studies showed that fucoxanthin has anti-obesity activity. It may do this through mitochondrial uncoupling protein 1 (UCP1) expression in white adipose tissues (WAT). UCP1 is usually expressed only in brown adipose tissue (BAT) and it is a key molecule for metabolic thermogenesis to avoid an excess of fat accumulation. However, there is little BAT in adult humans. Therefore, UCP1 expression in tissues other than BAT is expected to reduce abdominal fat. In the fucoxanthin-fed mice, WAT weight significantly decreased and UCP1 was expressed in the WAT, while there was no difference in WAT weight and little expression of UCP1 in the glycolipids-fed mice. This result indicates that fucoxanthin upregulates the expression of UCP1 in WAT, which may contribute to reducing WAT weight [24] . Combination of fucoxanthin and fish oil was shown to be more effective for attenuating the weight gain of WAT than feeding with fucoxanthin alone [25] . The anti-obesity effect of fucoxanthin was increased by mixing fucoxanthin with medium-chain triacylglycerols. This may due to the increase in the absorption rate of fucoxanthin by medium-chain triacylglycerols [26] . The anti-obesity effect of fucoxanthin could be mediated by altering lipid-regulating enzymes and UCPs in the visceral fat tissues and plasma adipokine levels. In epididymal adipose tissue of fucoxanthin-fed mice, adipocyte sizes and mRNA expression of lipogenic and fatty acid beta-oxidation enzymes were significantly down-regulated in a dose-dependent manner. Plasma leptin levels were significantly lower in the fucoxanthin groups than in the control group, while the adiponectin level was elevated [27] . Fucoxanthin regulates mRNA expression of inflammatory adipocytokines involved in insulin resistance, iNOS, and COX-2 in WAT and has specific effects on diabetic/obese KK-A(y) mice, but not on lean C57BL/6J mice [28] . Randomized controlled trails are needed to confirm if fucoxanthin has an anti-obesity activity in humans.
| Soy Isoflavone | | |
Soy isoflavones are secondary metabolites formed during soybean growth, they have a similar structure with estrogen; they have a non-steroidal structure but possess a phenolic ring that enables them to bind the estrogen receptor (ER) and act as estrogen agonists, therefore soy isoflavones are also called phytoestrogen.[Figure 4]
Studies in humans and rodents support the hypothesis that soy isoflavones (phytoestrogens) may be beneficial for the prevention of obesity and diabetes by affecting glucose and lipid metabolism [29],[30] . In fact, estradiol itself is a well known modulator of glucose homeostasis, which also affects obesity development. For instance, postmenopausal women develop visceral obesity and insulin resistance and are at an increased risk of diabetes, but estrogen replacement therapy normalizes these abnormalities [31] .
Postmenopausal Japanese women treated for 24 weeks with 100 mg/day of soy isoflavones exhibited a reduction in fat mass and body mass index [32] . A 6-month clinical trial was conducted to compare the effects of isoflavones with that of conjugated estrogens on blood glucose, insulin, and lipid profiles in postmenopausal Taiwanese women. The study revealed that during fasting, both glucose and insulin levels were significantly reduced by soy isoflavones (100 mg/day) and conjugated estrogens (0.625 mg/day) [33] . In contrast to the above mentioned trials, a number of studies reported an absence of beneficial effects of soy isoflavones on classical metabolic parameters such as bodyweight, serum lipid profiles, fat mass, blood glucose and insulin profiles [34],[35] . These discrepancies make it difficult to draw firm conclusions regarding the beneficial effect of soy isoflavones on these parameters. When comparing these different clinical trials, the underlying causes of conflicting results are probably related to the variability of experimental designs and exposition protocols (route of administration, composition, dose, and duration), the capacity of individuals to produce equol and the genetic susceptibility. Clearly more standardized studies are needed to further evaluate these putative beneficial effects of soy isoflavones on body weight management.
| Conjugated Linoleic Acid | | |
Conjugated linoleic acid (CLA) is mainly derived from ruminant animals and dairy products, however commercially available CLA is synthesized. CLA has different isomers, the main ones are c9,t11 and t10,c12.[Figure 5]  | Figure 5A: c9,t11-conjugated linoleic acid
Figure 5B: t10,c12-conjugated linoleic acid
Click here to view |
The anti-obesity effects of CLA have been supported in studies on animals when given at high enough doses [36],[37],[38] . In particular, dietary CLA decreases body fat and increases lean body mass in animals depending on the isomer, dose, and duration of treatment. Most of these studies used synthetically prepared CLA, a mixture of different isomers. Commercially prepared CLA supplements usually contain two major isomers, c9,t11 and t10,c12 in equal amounts. The t10,c12 isomer may be the active form affecting energy metabolism, weight gain and body fat deposition in animals, as indicated by the results of two studies in which mice were supplemented with CLA mixtures varying in the ratio of t10,c12 and c9,t11 isomers. Studies that have not shown a significant reduction in weight gain in animal model generally are those having applied either low levels (≤0.5% in the diet) of CLA or CLA mixtures that contained low concentrations of the t10,c12 isomer [39] .
In a randomized controlled trial (RCT), 60 overweight or obese subjects (body mass index 25-35 kg/m 2 ) were divided into five groups receiving placebo (9 g olive oil), 1.7, 3.4, 5.1 or 6.8 g CLA (ratio of t10,c12 and c9,t11 was 1:1) per day for 12 weeks, respectively. No differences among treatment groups were found regarding adverse events. Repeated-measures analysis showed that a significantly higher reduction in body fat mass (BFM) was found in the CLA groups compared with the placebo group (P=0.03). The reduction of body fat within the groups was significant for the 3.4 and 6.8 g CLA groups (P =0.05 and P=0.02, respectively). No significant differences among the groups were observed in regards to lean body mass, body mass index, blood safety variables or blood lipids. The data suggests that CLA may reduce BFM in humans and that no additional effect on BFM is achieved with doses higher than 3.4g CLA/d [40] . However, two other long-term (1 and 2 years) RCT showed no significant difference in body weight and BFM between supplementation of 3.4 g/d of CLA (mixture of 40% t10,c12 and 40% c9,t11 in triacylglycerol form) and placebo groups in healthy obese and overweight subjects [41],[42] .
Potential anti-obesity mechanisms of CLA include decreased pre-adipocyte proliferation and differentiation into mature adipocytes, decreased fatty acid and triglyceride synthesis, and increased energy expenditure and energy loss in the excreta [43] . CLA induces ectopic expression of uncoupling protein 1 (UCP1) in white adipose tissue (WAT), which may contribute to increased energy expenditure and weight loss [44] .
CLA does have a beneficial effect on body weight control, however this depends on the dosage and levels of CLA isomers. Studies in humans and animals have demonstrated that t10,c12-CLA is the anti-adipogenic isomer of CLA.
| Glabridin | | |
Glabridin is the major flavonoid of licorice (Glycyrrhiza glabra). Human and animal studies have shown that glabridin from licorice flavonoids has a beneficial effect on body weight control.
KK-A y mice aged 6 weeks were assigned to 5 groups (n=6), and fed a high-fat diet containing 0 (control), 0.5%, 1% or 2% of licorice flavonoids (containing 1.2% of glabridin), or 0.5% CLA for 4 weeks. Compared with the control group, body weight gain and weights of abdominal adipose tissues were suppressed (p<0.05) in 2% licorice flavonoids group, and blood glucose levels after 2 and 4 weeks were decreased in all three licorice flavonoids groups. CLA suppressed body weight gain (p<0.05), however it increased blood glucose level (p<0.05) after 2 weeks compared with the control group. Licorice flavonoids also stimulated human adipocyte differentiation in vitro. These results indicate that licorice flavonoids have abdominal fat-lowering and hypoglycemic effects, possibly mediated via activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) [45] . Gene expression of beta-oxidation enzyme was up-regulated and fatty acid synthesis enzyme was down-regulated in the 2% licorice flavonoids group in C57BL/6J mice liver. These findings suggest that licorice flavonoids prevent and ameliorate diet-induced obesity via the regulation of lipid metabolism-related gene expression in the liver [46] .[Figure 6]
In a placebo-controlled, double-blind trail, 103 overweight subjects aged 24-64 years (BMI 24-30) were divided into licorice flavonoids (n=51) and placebo (n=52) groups. Licorice flavonoids group ingested 300 mg/day of licorice flavonoids for 12 weeks. Body weight and BMI showed significant differences (P<0.05) between the licorice flavonoids group and the placebo group at each time-point. To confirm the safety of licorice flavonoids for practical use, the authors have also conducted a placebo-controlled, double-blind safety study in 40 overweight subjects who they were divided into licorice flavonoids (1800mg/day) and placebo groups for 4-weeks. Licorice flavonoids group exhibited a significant weight-reducing effect, and no clinically significant adverse events were observed during the 4-week study period [47] .
| Astaxanthin | | |
Astaxanthin is a natural antioxidant carotenoid that occurs in a wide variety of living organisms. It has many highly potent pharmacological effects, including antioxidant, anti-tumor and anti-cancer, anti-diabetic, and anti-inflammatory activities. [Figure 7]
Recent animal studies have also shown that astaxanthin may have a beneficial effect on body weight control. Fifty 4 week old female ddY mice were divided into five groups (n=10), normal diet (control group), high-fat diet group (placebo) and the other three groups were high-fat diet supplemented with 1.2, 6, 30 mg/kg body weight of astaxanthin, respectively. Astaxanthin at levels of 6 mg/kg or 30 mg/kg body weight significantly reduced the body weight gain induced by the high-fat diet. In addition, astaxanthin reduced liver weight, liver triacyglycerol, plasma triacyglycerol and total cholesterol [48] . Another study with similar design from the same research group found that astaxanthin treatment stimulated an enhancement of fatty acid utilization in mice [49] . Further studies are warranted to elucidate the mechanisms of astaxanthin on body weight management.
| Cynidin-3-Glucoside | | |
Cynidin-3-Glucoside, one of the anthocyanins, is a pigment widespread in the plant kingdom. [Figure 8]
In mice, cyanidin 3-glucoside-rich purple corn color (PCC) significantly suppressed the high fat diet-induced increase in body weight gain, and white and brown adipose tissue weights. PCC suppressed the mRNA levels of enzymes involved in fatty acid and triacylglycerol synthesis and lowered the sterol regulatory element binding protein-1 mRNA level in white adipose tissue [50] . In isolated rat adipocytes, anthocyanins enhanced adiponectin and leptin secretion, and up-regulated the adipocyte specific gene expression without activation of PPARgamma. The gene expression of adiponectin was also up-regulated in white adipose tissue in mice fed an anthocyanin supplemented diet [51] . Anthocyanins also up-regulated the hormone sensitive lipase, and enhanced the lipolytic activity [52] .
In human adipocytes, treatment with anthocyanins significantly up-regulated adiponectin and down-regulated plasminogen activator inhibitor-1 and interleukin-6, and also significantly induced uncoupling protein2, acylCoA oxidase1 and perilipin, which are related to lipid metabolism [53] .
| Conclusions | | |
The potential for natural products as sources of nutraceuticals or drugs to manage body weight is now being realized which including catechins, capsaicin, conjugated linoleic acid, fucoxanthin, soy isoflavone, glabridin, astaxanthin and cyaniding-3-glucoside etc. Theses natural products are effective and safe on body weight management in both human and animal studies. Further studies need to be conducted to investigate the mechanism of action, metabolism, long term safety and side effect of these natural products, as well as interactions between these natural products with dietary components.
| References | | |
| 1. | World Health Organization. Obesity and overweight. September 2006 (Accessed July 24, 2010, at http://www.who.int/mediacentre/factsheets/fs311/en 
|
| 2. | Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007; 335 (7631): 1194-1199.
|
| 3. | Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007; 369(9555):71-77.
|
| 4. | Koo MW, Cho CH. Pharmacological effects of green tea on the gastrointestinal system. Eur J Pharmacol. 2004; 500(1-3):177-185.
|
| 5. | Yang TT, Koo MW. Hypocholesterolemic effects of Chinese tea. Pharmacol Res. 1997;35(6):505-512.
|
| 6. | Ashida H, Furuyashiki T, Nagayasu H, et al. Anti-obesity actions of green tea: Possible involvements in modulation of the glucose uptake system and suppression of the adipogenesis-related transcription factors. Biofactors 2004; 22: 135-140.
|
| 7. | Auvichayapat P, Prapochanung M, Tunkamnerdthai O, et al. Effectiveness of green tea on weight reduction in obese Thais: A randomized, controlled trial. Physiol Behav 2008; 93:486-491.
|
| 8. | Diepvens K, Kovacs EM, Vogels N, Westerterp-Plantenga MS. Metabolic effects of green tea and of phases of weight loss. Physiol Behav 2006; 87: 185-191.
|
| 9. | Kovacs EM, Lejeune MP, Nijs I, Westerterp-Plantenga MS. Effects of green tea on weight maintenance after body-weight loss. Br J Nutr 2004; 91(3):431-437.
|
| 10. | Klaus S, Pültz S, Thöne-Reineke C, Wolfram S. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. Int J Obes 2005; 29(6): 615-623.
|
| 11. | Juhel C, Armand M, Pafumi Y, Rosier C, Vandermander J, Lairon D. Green tea extract (AR25t) inhibits lipolysis of triglycerides in gastric and duodenal medium in vitro. J Nutr Biochem 2000; 11(1): 45-51.
|
| 12. | Furuyashiki T, Nagayasu H, Aoki Y, et al. Tea Catechin Suppresses Adipocyte Differentiation Accompanied by Down-regulation of PPARã2 and C/EBPá in 3T3-L1 Cells. Biosci Biotechnol Biochem 2004; 68(11):2353-2359.
|
| 13. | Lin J, Della-Fera MA, Baile CA. Green tea polyphenol epigallocatechin gallate inhibits adipogenesis and induces apoptosis in 3T3-L1 adipocytes. Obes Res 2005;13(6):82-90.
|
| 14. | Wu BT, Hung PF, Chen HC, Huang RN, Chang HH, Kao YH. The Apoptotic Effect of Green Tea (−)-Epigallocatechin Gallate on 3T3-L1 Preadipocytes Depends on the Cdk2 Pathway. J Agric Food Chem 2005;53(14):5695-5701.
|
| 15. | Donnerer J, Amann R, Schuligoi R, Lembeck F. Absorption and metabolism of capsaicinoids following intragastric administration in rats. Naunyn Schmiedebergs Arch Pharmacol 1990; 342(3): 357-361.
|
| 16. | Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 1991;43(2):143-201.
|
| 17. | Gram DX, Hansen AJ, Wilken M, et al. Plasma calcitonin gene-related peptide is increased prior to obesity, and sensory nerve desensitization by capsaicin improves oral glucose tolerance in obese Zucker rats. Eur J Endocrinol 2005;153(6):963-969.
|
| 18. | Leung FW. Capsaicin-sensitive intestinal mucosal afferent mechanism and body fat distribution. Life Sci 2008; 83(1-2):1-5.
|
| 19. | Cui J, Himms-Hagen J. Long-term decrease in body fat and in brown adipose tissue in capsaicin-desensitized rats. Am J Physiol 1992;262(4 Pt 2): R568-573.
|
| 20. | Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003;35(6):807-825.
|
| 21. | Sasahara I, Furuhata Y, Iwasaki Y, et al. Assessment of the biological similarity of three capsaicin analogs (Capsinoids) found in non-pungent chili pepper (CH-19 Sweet) fruits. Biosci Biotechnol Biochem 2010; 74(2):274-278.
|
| 22. | Zhang LL, Liu DY, Ma LQ, et al. Activation of Transient Receptor Potential Vanilloid Type-1 Channel Prevents Adipogenesis and Obesity. Circ Res 2007;100:934-936.
|
| 23. | Motter AL, Ahern GP.TRPV1-null mice are protected from diet-induced obesity. FEBS Lett 2008; 582: 2257-2262.
|
| 24. | Maeda H, Hosokawa M, Sashima T, Funayama K, Miyashita K. Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun 2005; 332(2):392-397.
|
| 25. | Maeda H, Hosokawa M, Sashima T, Miyashita K. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J Agric Food Chem 2007;55 (19):7701-7706.
|
| 26. | Maeda H, Hosokawa M, Sashima T, Funayama K, Miyashita K. Effect of medium-chain triacylglycerols on anti-obesity effect of fucoxanthin. J Oleo Sci 2007; 56(12): 615-621.
|
| 27. | Woo MN, Jeon SM, Shin YC, Lee MK, Kang MA, Choi MS. Anti-obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice. Mol Nutr Food Res 2009;53(12):1603-1611.
|
| 28. | Hosokawa M, Miyashita T, Nishikawa S, et al. Fucoxanthin regulates adipocytokine mRNA expression in white adipose tissue of diabetic/obese KK-A(y) mice. Arch Biochem Biophys 2010 May 31 [Epub ahead of print]
|
| 29. | Bhathena SJ, Velasquez MT. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 2002;76:1191-1201.
|
| 30. | Velasquez MT, Bhathena SJ. Role of dietary soy protein in obesity. Int J Med Sci 2007; 4:72-82.
|
| 31. | Gambacciani M, Ciaponi M, Cappagli B, et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 1997;82(2):414-417.
|
| 32. | Mori M, Aizawa T, Tokoro M, Miki T, Yamori Y. Soy isoflavone tablets reduce osteoporosis risk factors and obesity in middle-aged Japanese women. Clin Exp Pharmacol Physiol 2004;31 Suppl 2:S39-41.
|
| 33. | Cheng SY, Shaw NS, Tsai KS, Chen CY. The hypoglycemic effects of soy isoflavones on postmenopausal women. J Women Health (Larchmt) 2004; 13(10):1080-1086.
|
| 34. | Charles C, Yuskavage J, Carlson O, et al. Effects of high-dose isoflavones on metabolic and inflammatory markers in healthy postmenopausal women. Menopause 2009;16(2):395-400.
|
| 35. | Weickert MO, Reimann M, Otto B, et al. Soy isoflavones increase preprandial peptide YY (PYY), but have no effect on ghrelin and body weight in healthy postmenopausal women. J Negat Results Biomed 2006;5:11.
|
| 36. | Park Y, Albright KJ, Liu W, Storkson JM, Cook ME, Pariza MW. Effect of conjugated linoleic acid on body composition in mice. Lipids 1997;32:53-858.
|
| 37. | West DB, Delany JP, Camet PM, Blohm F, Truett AA, Scimeca J. Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol 1998; 275:R667-R672.
|
| 38. | Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW. Evidence that the trans-10, cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids 1999; 34:235-241.
|
| 39. | Larsen TM, Toubro S, Astrup A. Efficacy and safety of dietary supplements containing CLA for the treatment of obesity: evidence from animal and human studies. J Lipid Res 2003;44:2234-2241.
|
| 40. | Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr 2000;130(12):2943-2948.
|
| 41. | Larsen TM, Toubro S, Gudmundsen O, Astrup A. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain. Am J Clin Nutr 2006;83:606-612.
|
| 42. | Gaullier JM, Halse J, Høye K, et al. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr 2005;135(4):778-784.
|
| 43. | Terpstra AH, Beynen AC, Everts H, Kocsis S, Katan MB, Zock PL. The decrease in body fat in mice fed conjugated linoleic acid is due to increases in energy expenditure and energy loss in the excreta. J Nutr 2002; 132:940-945.
|
| 44. | Wendel AA, Purushotham A, Liu LF, Belury MA. Conjugated linoleic acid induces uncoupling protein 1 in white adipose tissue of ob/ob mice. Lipids. 2009; 44: 975-982.
|
| 45. | Nakagawa K, Kishida H, Arai N, Nishiyama T, Mae T. Licorice flavonoids suppress abdominal fat accumulation and increase in blood glucose level in obese diabetic KK-A(y) mice. Biol Pharm Bull 2004; 27: 1775-1778.
|
| 46. | Aoki F, Honda S, Kishida H, et al. Suppression by licorice flavonoids of abdominal fat accumulation and body weight gain in high-fat diet-induced obese C57BL/6J mice. Biosci Biotechnol Biochem 2007; 71: 206-214.
|
| 47. | Tominaga Y, Mae T, Kitano M, Sakamoto Y, Ikematsu H, Nakagawa K. Licorice flavonoid oil effects body weight loss by reduction of body fat mass in overweight subjects. J Health Sci 2006;52: 672-683.
|
| 48. | Ikeuchi M, Koyama T, Takahashi J, Yazawa K. Effects of astaxanthin in obese mice fed a high-fat diet. Biosci Biotechnol Biochem. 2007; 71(4): 893-899.
|
| 49. | Ikeuchi M, Koyama T, Takahashi J, Yazawa K. Effects of astaxanthin supplementation on exercise-induced fatigue in mice. Biol Pharm Bull 2006; 29(10):2106-2110.
|
| 50. | Tsuda T, Horio F, Uchida K, Aoki H, Osawa T. Dietary cyanidin 3-O-beta-D-glucoside-rich purple corn color prevents obesity and ameliorates hyperglycemia in mice. J Nutr 2003; 133 (7): 2125-2130.
|
| 51. | Tsuda T, Ueno Y, Aoki H, et al. Anthocyanin enhances adipocytokine secretion and adipocyte-specific gene expression in isolated rat adipocytes. Biochem Biophys Res Commun 2004; 316(1):149-157.
|
| 52. | Tsuda T, Ueno Y, Kojo H, Yoshikawa T, Osawa T. Gene expression profile of isolated rat adipocytes treated with anthocyanins. Biochim Biophys Acta 2005; 1733(2-3):137-147.
|
| 53. | Tsuda T, Ueno Y, Yoshikawa T, Kojo H, Osawa T. Microarray profiling of gene expression in human adipocytes in response to anthocyanins. Biochem Pharmacol 2006;71(8):1184-1197.
|
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8]
| This article has been cited by | | 1 |
Plant-derived bioactive compounds regulate the NLRP3 inflammasome to treat NAFLD |
|
| Qian Huang, Xin Xin, QinMei Sun, Ziming An, Xiaojun Gou, Qin Feng | | Frontiers in Pharmacology. 2022; 13 | | [Pubmed] | [DOI] | | | 2 |
A review on phytochemicals, pharmacological activities, drug interactions, and associated toxicities of licorice (
Glycyrrhiza
sp.) |
|
| Islam Husain,Kiran Bala,Ikhlas A. Khan,Shabana I. Khan | | Food Frontiers. 2021; | | [Pubmed] | [DOI] | | | 3 |
Natural products in the management of obesity: Fundamental mechanisms and pharmacotherapy |
|
| Yinghan Chan,Sin Wi Ng,Joycelin Zhu Xin Tan,Gaurav Gupta,Poonam Negi,Lakshmi Thangavelu,Sri Renukadevi Balusamy,Haribalan Perumalsamy,Wei Hsum Yap,Sachin Kumar Singh,Vanni Caruso,Kamal Dua,Dinesh Kumar Chellappan | | South African Journal of Botany. 2021; 143: 176 | | [Pubmed] | [DOI] | | | 4 |
Cerasus humilis Cherry Polyphenol Reduces High-Fat Diet-Induced Obesity in C57BL/6 Mice by Mitigating Fat Deposition, Inflammation, and Oxidation |
|
| Suwen Liu,Xuedong Chang,Jincheng Yu,Weifeng Xu | | Journal of Agricultural and Food Chemistry. 2020; 68(15): 4424 | | [Pubmed] | [DOI] | | | 5 |
Astaxanthin exerts protective effects similar to bexarotene in Alzheimeræs disease by modulating amyloid beta and cholesterol homeostasis in blood-brain barrier endothelial cells |
|
| Elham Fanaee-Danesh,Chaitanya Chakravarthi Gali,Jelena Tadic,Martina Zandl-Lang,Alexandra Kober,Vicente Roca Agujetas,Cristina de Dios,Carmen Tam-Amersdorfer,Anika Stracke,Nicole Maria Albrecher,Anil Paul Chirackal Manavalan,Marielies Reiter,Yidan Sun,Anna Colell,Frank Madeo,Ernst Malle,Ute Panzenboeck | | Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2019; | | [Pubmed] | [DOI] | | | 6 |
Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity |
|
| Xing-Xing Fan,Hu-Dan Pan,Ying Li,Rui-Jin Guo,Elaine Lai-Han Leung,Liang Liu | | Pharmacology & Therapeutics. 2018; | | [Pubmed] | [DOI] | | | 7 |
Recovery of capsaicin from Capsicum frutescens by applying aqueous two-phase systems based on acetonitrile and cholinium-based ionic liquids |
|
| Poliane Lima Santos,Lana Naiadhy Silva Santos,Sónia Patrícia Marques Ventura,Ranyere Lucena de Souza,João Araújo Pereira Coutinho,Cleide Mara Faria Soares,Álvaro Silva Lima | | Chemical Engineering Research and Design. 2016; | | [Pubmed] | [DOI] | | | 8 |
Capsaicinoids improve egg production by regulating ovary nuclear transcription factors against heat stress in quail |
|
| N. Sahin,C. Orhan,M. Tuzcu,V. Juturu,K. Sahin | | British Poultry Science. 2016; : 1 | | [Pubmed] | [DOI] | | | 9 |
Fucoxanthin and lipid metabolism: A minireview |
|
| Kh. Muradian,A. Vaiserman,K.-J. Min,V.E. Fraifeld | | Nutrition, Metabolism and Cardiovascular Diseases. 2015; 25(10): 891 | | [Pubmed] | [DOI] | | | 10 |
Microalgal carotenoids: beneficial effects and potential in human health |
|
| Jie Zhang,Zheng Sun,Peipei Sun,Tianpeng Chen,Feng Chen | | Food & Function. 2014; 5(3): 413 | | [Pubmed] | [DOI] | | | 11 |
Phytochemistry and biological properties of glabridin |
|
| Charlotte Simmler,Guido F. Pauli,Shao-Nong Chen | | Fitoterapia. 2013; 90: 160 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
Search Pubmed for